Abstract
Sentinel lymph node biopsy (SLNB) represents the standard axillary staging procedure for patients with clinically node-negative breast cancer. Whereas SLNB has been demonstrated to be reliable and to reduce axillary staging morbidity compared to standard axillary lymph node dissection (ALND), there is uncertainty as to how to optimize axillary staging in the context of primary systemic therapy (PST) and minimize the morbidity of ALND in case of positive SLNB.
| Translated title of the contribution | Axillary staging in patients with breast cancer. Before or after neoadjuvant chemotherapy? |
|---|---|
| Original language | German |
| Journal | Gynakologische Praxis |
| Volume | 40 |
| Issue number | 3 |
| Pages (from-to) | 495-502 |
| Number of pages | 8 |
| ISSN | 0341-8677 |
| Publication status | Published - 2016 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Fingerprint
Dive into the research topics of 'Axillary staging in patients with breast cancer. Before or after neoadjuvant chemotherapy?'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver